ArticleParkinson's disease2011
Models for LRRK2-Linked Parkinsonism.
Article in Parkinson's disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Role of Oxidative Stress in Human Neurodegenerative Pathologies: Lessons from theCurrent topics in medicinal chemistry · 2026Review
- Exploring the focal role of LRRK2 kinase in Parkinson's disease.Environmental science and pollution research international · 2022Review
- Article
- A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration inAging · 2020Article
- Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study.Neuro-degenerative diseases · 2020Article
- Review
- The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2018Article
- Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.Human molecular genetics · 2016Article
- Mouse Genetic Models of Human Brain Disorders.Frontiers in genetics · 2016Review
- Article
- Drosophila Mutant Model of Parkinson's Disease Revealed an Unexpected Olfactory Performance: Morphofunctional Evidences.Parkinson's disease · 2016Article
- 68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.Frontiers in aging neuroscience · 2016Article
- A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.PloS one · 2015Article
- Article
- Non-motor and motor features in LRRK2 transgenic mice.PloS one · 2013Article
- Synphilin-1 alters metabolic homeostasis in a novel Drosophila obesity model.International journal of obesity (2005) · 2012Article
- Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.ACS chemical neuroscience · 2012Review
- Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?BMC medicine · 2012Review
- LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease.Frontiers in neurology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by the selective loss of dopaminergic neurons and the presence of Lewy bodies. The pathogenesis of PD is not fully understood, but it appears to involve both genetic susceptibility and environmental factors. Treatment for PD that prevents neuronal death progression in the dopaminergic system and abnormal protein deposition in the brain is not yet available. Recently, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified to cause autosomal-dominant late-onset PD and contribute to sporadic PD. Here, we review the recent models for LRRK2-linked Parkinsonism and their utility in studying LRRK2 neurobiology, pathogenesis, and potential therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.